Konstantin Adamsky
Directeur/Bestuurslid bij FILAMENT HEALTH CORP.
Actieve functies van Konstantin Adamsky
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| FILAMENT HEALTH CORP. | Directeur/Bestuurslid | 23-08-2022 | - |
| Independent Dir/Board Member | 23-08-2022 | - |
Loopbaan van Konstantin Adamsky
Eerdere bekende functies van Konstantin Adamsky
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Regenera Pharma Ltd.
 Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Algemeen Directeur | - | 01-08-2017 |
| Operationeel Directeur | 01-08-2017 | 01-10-2020 | |
| Levco Pharmaceuticals Ltd. | Operationeel Directeur | - | - |
Opleiding van Konstantin Adamsky
| Weizmann Institute of Science | Doctorate Degree |
Statistieken
Internationaal
| Israël | 4 |
| Canada | 2 |
Operationeel
| Chief Executive Officer | 3 |
| Chief Operating Officer | 2 |
| Director/Board Member | 2 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| FILAMENT HEALTH CORP. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Health Technology |
| Levco Pharmaceuticals Ltd. |
- Beurs
- Insiders
- Konstantin Adamsky
- Ervaring
